Biodefense Stock Q&A; PositiveID (OTCBB: PSID) Chairman and CEO Discusses New Firefly Dx Detection System

Point Roberts, WA - June 6, 2013 (Investorideas.com Newswire) Investorideas.com, a leader in research for independent investors presents an exclusive Q&A interview with Mr. William J. Caragol, Chairman and CEO of PositiveID Corporation (OTCBB: PSID) discussing the recent launch of the development of the Firefly Dx detection system. Firefly is a portable, hand-held, point-of-need molecular diagnostic system, designed to provide test results from sample input through reporting of results in less than 15 to 30 minutes depending on the type of test performed.

Q: Investorideas.com
Firefly is based on technology from your M-BAND (Microfluidics-based Bioagent Networked Detector) airborne bio-threat detector; can you explain the evolution of this technology and what inspired it?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Throughout meetings with past and potential new customers representing a variety of different industries, we listened to their needs and the circumstances they often face including military field deployments, evolving conditions in remote areas ,agricultural testing, etc and it became clear that there is a real and pressing need for portable, handheld, rapid biological testing solutions.
We have been able to evolve and miniaturize the patented technology advances we’ve achieved in the development of our M-BAND, which is basically a “lab-in-a-box,” and Dragonfly cartridge based systems to create a handheld, battery-powered, rapid biological testing system that can communicate test results from sample purification to final results in less than 30 minutes to a SMART phone or personal computer. Furthermore, the system is designed to be easy to use and does not require a high level of technical expertise to operate.
Q: Investorideas.com
According to your April 29, 2013 press release, Firefly is expected to quickly process human and agricultural samples to provide accurate confirmation of biological threats via a smart-phone application. What is a realistic time frame to see this app available to military in the field?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
The business strategy that we have employed for our biological detection technologies in the past and intend to continue moving forward is to innovate and develop novel technologies for markets in detection and diagnostics, and to partner with large firms that have a foothold in the market with scalable manufacturing capabilities. We believe that with the appropriate funding partner, we could complete the development of handheld prototypes and cartridges and have the devices ready for field testing in approximately 12 months.
Q: Investorideas.com
What biological agents can the Firefly Dx system detect?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
The assay format of the Firefly Dx is polymerase chain reaction (PCR) using Real-time TaqMan® probe-based chemistry and is currently adapted to detect both DNA and RNA targets. PositiveID is currently developing diagnostic panels for the Firefly Dx against measles, respiratory diseases, and Arboviral diseases. Because the Firefly Dx instrument is a universal cartridge-based system, however, it will be able to accommodate new assays or panels very rapidly. Some examples of organisms for which we have previously developed immunoassays include anthrax, small pox, various forms of influenza, and MRSA, among many others.
Q: Investorideas.com
Can you give us an update on your M-BAND system and the status of BioWatch Generation 3?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
As you know, on January 25, 2013, the U.S. Department of Homeland Security released a draft request for proposal (“RFP”) for Stage 1 of BioWatch Generation 3. At that time it was announced that the final RFP for Stage 1 would be released in the government’s third quarter of fiscal 2013, which ends June 30th. If that timeline holds, the RFP is expected to be awarded in late 2013 and have a performance period of 18 months. We look forward to the release of the final RFP and will keep our investors informed of any updates.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. http://www.PositiveIDCorp.com
About InvestorIdeas.com:
Investorideas.com is a meeting place for investors and public companies in leading sectors? Find investing ideas in biotech and biodefense stocks, tech and mobile stocks, mining stocks, oil and gas, water stocks, renewable energy, beverage stocks, defense stocks, nanotech and more on TSX, OTC, NASDAQ and global exchanges.
Get free investor news and stock alerts
Sign Up:  http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed May 2013 for three months: $1500 plus 50,000 144 shares .
http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact
PSID:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com: 800 665 0411

Biodefense Stock PositiveID (OTCBB: PSID) Releases White Paper on Firefly Dx Detection System and M-BAND

Point Roberts, WA - June 3, 2013 (Investorideas.com Newswire) Investorideas.com, a leader in sector research for independent investors , features the recently published white paper for PositiveID Corporation (OTCBB: PSID) and the company’s biodefense technologies.

The Company’s proprietary airborne pathogen detection system, M-BAND
(Microfluidic Bio-agent Autonomous Networked Detector), was developed under
contract with the U.S. Department of Homeland Security ("DHS") Science & Technology directorate. M-BAND continuously and autonomously analyzes air samples to detect biological threats in the form of bacteria, viruses, and toxins. The Firefly Dx handheld detection system is the Company’s next-generation technology. The Company’s technology is protected by a portfolio of over 20 key patents/patents pending.
Link to white paper /PDF http://www.investorideas.com/CO/PSID/PSID_MFS_White_Paper_Firefly_Q1_2013_FINAL.pdf
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid medical testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. http://www.PositiveIDCorp.com
About InvestorIdeas.com:
Investorideas.com is a meeting place for investors and public companies in leading sectors. Find investing ideas in biotech and biodefense stocks, tech and mobile stocks, mining stocks, oil and gas, water stocks, renewable energy, beverage stocks, defense stocks, nanotech and more on TSX, OTC, NASDAQ and global exchanges.
Get free investor news and stock alerts
Sign Up:  http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed May 2013 for three months: $1500 plus 50,000 144 shares .
http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
CONTACT:
PositiveID Corporation
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com: 800 665 0411

Defense Stock Alert: Homeland Security Corporation (OTC: HSCC) Launches new Website, Rolling out New Business plan following Biometrics/Security Acquisition

WRIGHTWOOD, CA - May 29, 2013 (Investorideas.com newswire) Homeland Security Corporation (OTCMarkets:HSCC), a security technology company announced today the launch of the company's new website and logo at www.hsccsecurity.com as part of the new business strategy following the recent acquisition of Sense Security Technologies, a custom developer and solution provider of integrated hardware and proprietary software in the biometrics/security industry.

The new website now offers customers new security solutions, a more user friendly look and feel and new informative information regarding the new product portfolio. The website also expands on the company's intent to enhance its presence in the medical marijuana field for securing the process of seed to sale authentication and auditing.
The new technologies and applications target the Transportation, Pharmaceutical, Law Enforcement, Healthcare, Travel and Tourism, Time and Attendance, Access Control, and Medical Marijuana Industries, including various State marijuana security/compliance markets. The HSCC website also includes all the video surveillance, camera, and security technologies that Homeland Security Corporation has offered for years.
Recently appointed President, Mr. Dore Perler said, "Our new website now encompasses all the solutions that HSCC offers in a easy manageable and simple to navigate package. " The company is prepared to add additional customers and revenues as our goal for 2013" add Mr Perler.
About Homeland Security Corporation
HSC is a leading innovator, consultant and implementer of security driven technologies that can be deployed in any environment to meet a client's security or regulatory needs. Our primary mission is to protect people, property, infrastructure, and our clients' high value assets by mitigating threats, guiding regulatory agencies, and integrating new and novel technologies.
SAFE HARBOR
Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, along with statements regarding Homeland's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those anticipated.
Investor relations Contact:
Darren Bankston
404-313-2198
Published at Investorideas.com Newswire
More info on HSCC at Investorideas.com Visit: http://www.investorideas.com/CO/HSCC/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. All investment involves risk and loss of investment. Disclosure: HSCC has compensated investorideas.com the equivalent of $ten thousand per month in 144 shares for publishing news and content. Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp HSCC is not a fully reporting company. More info can be viewed at otcmarkets.com and the company websites.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biometrics Stock Alert: Homeland Security Corporation (OTC: HSCC) Acquires Security and Biometric Assets and Solutions

WRIGHTWOOD, CA - May 14, 2013 (Investorideas.com newswire) Homeland Security Corporation (OTCMarkets:HSCC), a security technology company announced today the acquisition of all the security and biometric assets of Sense Security Technologies. Sense Technologies is a custom developer and solution provider of integrated hardware and proprietary software targeting the Transportation, Pharmaceutical, Law Enforcement, Healthcare, Travel and Tourism, Time and Attendance, Access Control, and Medical Marijuana Industries, including various State marijuana security/compliance markets.

On March 18th the company announced it had formed a joint venture with Sense Technologies for the development, sale and support of additional identification methods, including Biometrics and Access control solutions to HSCC's existing product line. The company has now formalized this joint venture into an acquisition, using shares/equity to complete the transaction.
The assets of Sense Security Technologies will now allow HSCC to enter the law enforcement, Time and Attendance, Access Control, and multiple other markets using biometric and card based technologies, including the Medical Marijuana industry for the development of security enhanced vending devices.
The assets specifically will include the following applications and technologies: Biometrics – fingerprint, IRIS, facial, Access control – fingerprint, IRIS, smartcard, mag, proximity card, Time and attendance – card or biometrics and Perimeter security – RFID.
Additionally HSCC has acquired all of the source code, documentation, customer base, industry contacts and suppliers.
Recently appointed President, Mr. Dore Perler said, "With the transition of the joint venture to an acquisition within the company, the company now has diverse base of assets within the security sector. We are now confident moving forward we can execute our new plan to become a competitor within the security sector."
About Homeland Security Corporation
HSC is a leading innovator, consultant and implementer of security driven technologies that can be deployed in any environment to meet a client's security or regulatory needs. Our primary mission is to protect people, property, infrastructure, and our clients' high value assets by mitigating threats, guiding regulatory agencies, and integrating new and novel technologies.
SAFE HARBOR
Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, along with statements regarding Homeland's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those anticipated.
http://www.homelandsecuritycorporation.com/
Please note the current website is under development
Investor relations Contact:
Darren Bankston
404-313-2198
Published at Investorideas.com Newswire
More info on HSCC at Investorideas.com Visit: http://www.investorideas.com/CO/HSCC/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. All investment involves risk and loss of investment. Disclosure: HSCC has compensated investorideas.com the equivalent of $ten thousand per month in 144 shares for publishing news and content. Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp HSCC is not a fully reporting company. More info can be viewed at otcmarkets.com and the company websites.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Homeland Security Stock, Homeland Security Corporation (OTC Markets: HSCC) Appoints New President with Biometrics and Access Control Solutions Expertise and Contacts

WRIGHTWOOD, CA - May 9, 2013 (Investorideas.com newswire) Homeland Security Corporation (OTCBB: HSCC), a security technology company reports the appointment of Mr. Dore Perler as the Company's new president, in charge of day to day operations. Mr. Perler brings over twenty years of industry experience and contacts to the company, from both public markets and the security sector.

Mr. Perler has a previous background as the CEO of a publicly traded company in Biometrics, Explosive Detection technologies and Access control solutions markets.
His extensive public company management experience includes International mergers and acquisitions, creation of financial management strategies, capital management and capital raises.
Mr. Perler will be reporting to David Shade, CEO and Chairman, to execute the new business strategy which includes building upon the security solutions division and the recently announced expansion in the Marijuana (both Medical Marijuana-MMJ and Marijuana-MJ) marketplace providing services ranging from legal and regulatory compliance to security surveillance.
Mr. Perler said, "It's one of my primary goals to take the company through the required steps and become compliant with regulatory bodies and become a fully reporting and funded entity. In parallel we are rebranding the company with a new website, new corporate identity and new plan to become a competitor in the security sector."
About Homeland Security Corporation
HSC is a leading innovator, consultant and implementer of security driven technologies that can be deployed in any environment to meet a client's security or regulatory needs. Our primary mission is to protect people, property, infrastructure, and our clients' high value assets by mitigating threats, guiding regulatory agencies, and integrating new and novel technologies.
SAFE HARBOR
Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, along with statements regarding Homeland's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those anticipated.
http://www.homelandsecuritycorporation.com/
Please note the current website is under development
Investor relations Contact:
Darren Bankston
404-313-2198
Published at Investorideas.com Newswire
More info on HSCC at Investorideas.com Visit: http://www.investorideas.com/CO/HSCC/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. All investment involves risk and loss of investment. Disclosure: HSCC has compensated investorideas.com the equivalent of $ten thousand per month in 144 shares for publishing news and content. Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp HSCC is not a fully reporting company. More info can be viewed at otcmarkets.com and the company websites.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

www.investorideas.com defense stocks blog- Homeland Security news

www.investorideas.com defense stocks blog- Homeland Security news
Two men arrested and charged Monday were part of an al Qaeda-supported plot to derail a passenger train, the Royal Canadian Mounted Police said.


The suspects, Chiheb Esseghaier and Raed Jaser, are accused of conspiring to kill people on a VIA train, police said. Officials said that the suspects had the capacity to carry out an attack but that the public was never in imminent danger.

The two men were receiving support "in the form of direction and guidance" from al Qaeda elements in Iran, police said. They are not Canadian citizens.
Follow complete coverage of breaking news on CNN TV, http://cnn.com and CNN Mobile.

Published at (www.investorideas.com defense stocks blog ) Research defense and Homeland Security stocks with the largest global defense stocks directory online for investors at Investorideas.com and www.Homelanddefensestocks.com click here: http://www.investorideas.com/Companies/HomelandDefense/Stock_List.asp Defense and security companies - Become a showcase defense stock at www.investorideas.com and www.homelanddefensestocks.com for as little as $1000 month

Medical Technology Breaking News: Aethlon Medical (OTCBB:AEMD) Discloses Cancer and Infectious Disease Therapy Presentation at ISEV 2013

SAN DIEGO - April 18, 2013 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), disclosed that a poster presentation entitled: "Extracorporeal Exosome Removal: A Therapeutic Strategy to Address an Evolutionary Survival Mechanism Shared by Cancer and Infectious Viral Pathogens," is being presented today at the International Society of Extracellular Vesicles (ISEV) 2013 conference being held in Boston, MA. Dr. Annette Marleau, Director of Tumor Immunology at Aethlon Medical will give the presentation. Information related to ISEV 2013 can be accessed online at: www.isevmeeting.org

The Aethlon presentation discusses the specificity of the Aethlon Hemopurifier® to address evolved glycopathogen targets that are instrumental in cancer and infectious disease progression. Significant points addressed in the presentation include emerging knowledge of exosome secretion, which is a notable feature of malignancy owing to the diverse roles of these particles in tumor-mediated immune suppression, angiogenesis, metastasis, and resistance to therapeutic agents. As cancer-secreted exosomes remain a critical target not addressed by drug therapies, the Company is expanding the potential utility of the Hemopurifier® to include cancer. In this role, the Hemopurifier® provides an adjuvant strategy to improve current and emerging cancer treatment outcomes without adding drug toxicity. To date, pre-clinical Hemopurifier® studies have validated the capture of exosomes underlying breast cancer, metastatic melanoma, ovarian cancer, lymphoma, and colorectal cancer.
The Aethlon Hemopurifier® consists of the lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of a plasma membrane device that is compatible for use with standard CRRT and dialysis units. GNA-based capture is mediated by unique high mannose signatures abundant on the surface of cancer-secreted exosomes as well as glycoproteins that reside on the outer membrane of infectious viral pathogens.
In human studies of treatment naive HIV and Hepatitis-C (HCV) infected individuals, Hemopurifier® therapy demonstrated average viral load reductions of greater than 50% during single four-hour treatment applications. A three-treatment Hemopurifier® protocol combined with interferon-based standard-of-care resulted in undetectable HCV in as little as seven days in hard-to-treat genotype-1 patients. In this same clinical program, post-treatment elution studies documented the capture of up to 300 billion HCV copies by the Hemopurifier® during a single six-hour treatment. A human feasibility study to initiate HCV human studies in the United States is pending IDE approval by the U.S. Food and Drug Administration (FDA).
Based on human treatment experience and exosome capture validations, the Company has identified candidate research centers to conduct a Hemopurifier® therapy study in cancer patients.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About The Aethlon Hemopurifier®
The Aethlon Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of infectious viral pathogens and immunosuppressive proteins from the entire circulatory system. In the treatment of Hepatitis C virus (HCV), human studies have demonstrated that Hemopurifier® therapy may improve immediate, rapid and sustained virologic response rates when administered in the first few days of standard-of-care drug therapy. In addition to accelerating viral load depletion, post-treatment analysis of the Hemopurifier® has documented the capture of up to 300 billion HCV copies of HCV during a single six-hour treatment. Access to Hemopurifier® therapy is available on a compassionate-use basis through the Medanta Medicity Institute (Medicity), a leading center for medical tourism in India. The Medicity is offering treatment access to infected individuals who previously failed or subsequently relapsed standard-of-care drug regimens. The Hemopurifier® is also being offered as a salvage therapy to infected individuals who suffer a viral breakthrough during standard-of-care therapy. U.S. studies of the Hemopurifier® are currently pending approval of an IDE submitted to FDA.
The Aethlon Hemopurifier® and Cancer
In addition to the opportunity to address a broad-spectrum of infectious viral pathogens, the Hemopurifier® has been discovered to capture tumor-derived exosomes underlying several forms of cancer. Tumor-derived exosomes have recently emerged to be a vital therapeutic target in cancer care. These microvesicular particles suppress the immune response in cancer patients through apoptosis of immune cells and their quantity in circulation correlates directly with disease progression. Beyond possessing immunosuppressive properties, tumor-derived exosomes facilitate tumor growth, metastasis, and the development of drug resistance. By addressing this unmet medical need, the Hemopurifier® is positioned as an adjunct to improve established cancer treatment regimens.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com Newswire
More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/
Disclaimer: Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. If you have any questions regarding information in this press release please contact the company listed in the press release. Aethlon Medical, Inc. is currently an annual news release client at Investorideas.com and compensates Investorideas.com $2425 quarterly to publish and distribute news with Investorideas and its syndication partners
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894